Uncategorized

  • 2
    May

    Click Conjugation of targeting moieties enables active cell transport of Oligonucleotide drugs.

    Oligonucleotide drug therapeutics are a potential drug class for wide range of diseases. With just 9 approved products they already generated more than. 2 billion

    MORE →
  • 22
    Mar

    baseclick and Tebubio Join Forces to Revolutionize Nucleic Acid Bioconjugation and Labeling

    Munich March.22.2024 This partnership represents a significant milestone in advancing the field of nucleic acid bioconjugation and labeling, providing researchers with unprecedented access to cutting-edge

    MORE →
  • 21
    Mar

    baseclick GmbH attends Analytica

    We’re thrilled to announce our participation in Analytica 2024, one of the leading trade fairs for laboratory technology, analysis, and biotechnology. This exciting event brings

    MORE →
  • 8
    Mar

    Our CEO Dr. Frischmuth shares our newest innovations at RNA Leader conference.

    Discover the future of molecular innovation with baseclick. Leading the way in antisense oligonucleotide and mRNA development using Nobel price-winning click chemistry. Visiting our CEO

    MORE →
  • 22
    Feb

    Join us for Bio CEO & Investor Conference in New York

    Excited to announce that our CEO Dr. Thomas Frischmuth is attending the Bio CEO & Investor Conference, where we will be showcasing our pioneering innovations

    MORE →